Abstract
Human adenoviruses (HAdVs) represent a significant clinical threat, particularly to immunosuppressed individuals, yet no effective, FDA-approved anti-HAdV therapy currently exists. This study presents a novel image-based high-throughput screening (HTS) platform designed to score the full viral replication cycle—from initial entry to the dissemination of progeny. By analyzing 1,280 small molecular weight compounds from the Prestwick Chemical Library (PCL), we identified Nelfinavir mesylate as a potent inhibitor of HAdV-C2 multi-round plaque formation. Notably, Nelfinavir, an FDA-approved anti-retroviral, does not inhibit single-round infection but specifically targets the spread of the virus. Our findings, validated through robust image analysis and dual-site replication, underscore the power of full-cycle infection assays in identifying viral inhibitors with high clinical potential. All screening data, including images and processing pipelines, are available at the Image Data Repository (IDR), accession number idr0081.
Introduction
Human adenoviruses (HAdVs) are ubiquitous pathogens that typically cause self-limiting respiratory, ocular, or gastrointestinal infections in healthy adults. However, in immunocompromised populations—such as pediatric patients undergoing allogeneic hematopoietic stem cell transplants—HAdV infections can lead to disseminated disease with mortality rates as high as 80%.
The current standard of care, Cidofovir, is often inadequate due to its significant nephrotoxicity and limited clinical efficacy. A major bottleneck in the development of new therapeutics is the reliance on "single-round" infection assays. These traditional screens often focus exclusively on early stages of the viral life cycle, such as entry or early gene expression, potentially overlooking compounds that interfere with later stages like assembly, egress, or cell-to-cell transmission.
Methodology: The Full-Cycle Assay
To address this gap, researchers developed a phenotypic screening pipeline utilizing High-Content Imaging (HCI). The core innovation of this platform is its ability to monitor the "full cycle" of infection over a 72-hour period, rather than the standard 24-hour window used in single-round assays.
Screening and Validation
The team screened the Prestwick Chemical Library (PCL), comprising 1,280 mostly FDA-approved small molecules. A549 lung epithelial cells were infected with a reporter adenovirus (HAdV-C2-dE3B-GFP). By extending the assay duration to 72 hours, the researchers allowed the virus to complete multiple rounds of replication, resulting in the formation of "plaques"—clusters of infected cells that signify successful viral transmission.
To ensure the robustness of the findings, the screen was performed in a quadruplicate, blinded format. Furthermore, the entire process was replicated independently at two different institutions: the University of Zurich (UZH) and the Ecole Polytechnique Fédérale de Lausanne (EPFL). This dual-site approach demonstrated high reproducibility, with R² correlations between sites ranging from 0.68 to 0.98.
Image Analysis with Plaque2.0
Quantification was performed using the Plaque2.0 software, which extracted five key phenotypic features from the images:
- Number of nuclei (to assess cell density and toxicity).
- Number of infected nuclei.
- Infection index.
- Number of plaques (clusters of infected cells).
- Integrated GFP intensity.
Key Results and Discovery
The screening platform achieved a mean Z’-factor of 0.52 for plaque numbers, confirming its suitability for high-throughput applications. After excluding 126 compounds due to toxicity (determined via Presto-blue viability assays), the team focused on the most effective non-toxic inhibitors.
The Identification of Nelfinavir
The standout hit from the screen was Nelfinavir mesylate, an HIV protease inhibitor. The data revealed a unique profile for Nelfinavir: while it had no significant effect on the initial infection of a single cell (single-round), it drastically reduced the formation of plaques (multi-round). This suggests that Nelfinavir does not block the virus from entering a cell or expressing its genome, but instead prevents the infected cell from transmitting the virus to neighboring cells. This specific inhibition of viral spread makes it a compelling candidate for preventing the systemic dissemination of HAdV in clinical settings.
Open Science and Data Accessibility
In a commitment to open science, the authors have made the complete dataset available to the public. This includes all primary images, image analysis parameters, and data processing pipelines. The data is hosted at the Image Data Repository (IDR) under accession number idr0081, providing a valuable resource for the broader virology and drug discovery communities.
Discussion and Future Directions
The discovery of Nelfinavir’s efficacy against HAdV highlights the critical importance of assay design. Had the researchers utilized a standard 24-hour single-round screen, Nelfinavir would likely have been discarded as an inactive compound. This study proves that phenotypic, full-cycle assays are essential for identifying drugs that target late-stage viral processes.
While Nelfinavir is already FDA-approved for anti-retroviral therapy, its exact molecular mechanism in the context of adenovirus remains to be fully elucidated. Preliminary data suggests it targets maturation or egress, and a follow-up study is currently in preparation to define these mechanics. Future research will also involve testing Nelfinavir in more complex biological systems, such as primary human tissues or the Syrian Hamster model, to further validate its potential as a repurposed treatment for life-threatening adenovirus infections.
Summary updated